Growth Metrics

PROCEPT BioRobotics (PRCT) Preferred Stock Liabilities (2020 - 2021)

PROCEPT BioRobotics (PRCT) reported Preferred Stock Liabilities of $328.6 million for Q2 2021, up 34.74% on a QoQ basis from $243.9 million in Q1 2021.

PROCEPT BioRobotics (PRCT) has 2 years of Preferred Stock Liabilities data on file, last reported at $328.6 million in Q2 2021.

  • Quarterly Preferred Stock Liabilities changed N/A year-over-year to $328.6 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $328.6 million (changed N/A YoY) and the FY2020 annual result came in at $243.9 million, changed N/A from the prior year.
  • Preferred Stock Liabilities grew to $328.6 million in Q2 2021 per PRCT's latest filing, from $243.9 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $328.6 million in Q2 2021 and bottomed at $243.9 million in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 PROCEPT BioRobotics 1.58 Bn 1.33 Bn 53.95 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 328.56 Mn
Mar 31, 2021 243.85 Mn
Dec 31, 2020 243.85 Mn
Sep 30, 2020 243.85 Mn